Single-center retrospective analysis of second-line treatment with regorafenib in patients with advanced colorectal cancer among the COVID-19 pandemic
e15552Background: Regorafenib targets multiple tyrosine kinases that has been approved for the third-line treatment in metastatic colorectal cancer (mCRC) patients in China. Here, We retrospectively analyzed the efficacy and safety of regorafenib alone or combined with chemotherapy/immunotherapy in...
Saved in:
| Published in | Journal of clinical oncology Vol. 42; no. 16_suppl; p. e15552 |
|---|---|
| Main Authors | , |
| Format | Journal Article |
| Language | English |
| Published |
American Society of Clinical Oncology
01.06.2024
|
| Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!